ImmunityBio Shareholders Now Have Opportunity in Class Action Against Securities Fraud

Legal Update on ImmunityBio, Inc. (IBRX) Shareholders

Background
ImmunityBio, Inc., a publicly traded biotechnology firm listed on NASDAQ under the ticker IBRX, has recently come under scrutiny following allegations of securities fraud. The Law Offices of Frank R. Cruz have announced that shareholders who experienced financial losses in this company now have an opportunity to lead a class action lawsuit against the firm. The firm encourages affected investors to act before the deadline, which is set for May 26, 2026.

Understanding the Allegations
The crux of the allegations revolves around statements made by the company and its leadership concerning the capabilities of its lead product candidate, Anktiva. According to the filed complaint, between January 19, 2026, and March 24, 2026, certain statements made by the defendants—including claims from the company’s founder Soon-Shiong—were reportedly misleading. Specifically, the complaint alleges that Soon-Shiong exaggerated Anktiva's effectiveness, leading to an unreasonably positive portrayal of both the company's operations and future prospects.

These misleading statements potentially contributed to large financial losses for shareholders who invested in ImmunityBio during the specified period. Given the gravity of these accusations, the law firm suggests that investors may have a valid reason to seek restitution through legal channels.

Call to Action for Investors
If you are an investor who has suffered losses related to ImmunityBio, now is the time to act. The Law Offices of Frank R. Cruz are seeking to assemble a group of lead plaintiffs to represent the affected shareholders in a class-action lawsuit against the company. Interested investors are encouraged to reach out to the firm to learn more about their rights and potential involvement in the lawsuit.

It's essential for investors to consult legal experts who specialize in securities law. They can explain the intricacies of the case, outline the process for joining the lawsuit, and help recover the losses incurred due to these alleged fraudulent activities.

You can contact the law firm directly via email or phone, and they also provide resources for further information about the ongoing securities fraud lawsuit. The firm emphasizes that participation does not require immediate action; potential plaintiffs can simply retain their counsel or choose to remain absent members of the class action.

Further Information
For those interested in participating or learning more about this legal matter, the Law Offices of Frank R. Cruz have provided multiple contact methods, including a direct email and telephone number. It's advisable to provide personal contact information and the number of shares affected when reaching out.

The unfolding situation with ImmunityBio underscores the complexities and risks associated with investing in biotechnology firms. As always, it’s crucial for investors to remain vigilant and informed about the companies in which they invest.

Conclusion

ImmunityBio shareholders who believe they were misled have a significant opportunity to hold the company accountable for securities fraud. With the lead plaintiff deadline fast approaching, affected investors should act promptly to ensure their voices are heard in this high-stakes case.